+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Gemzar"

Gemcitabine Hydrochloride Market Report 2025 - Product Thumbnail Image

Gemcitabine Hydrochloride Market Report 2025

  • Report
  • September 2025
  • 250 Pages
  • Global
From
Lung Cancer Drugs Market Report 2025 - Product Thumbnail Image

Lung Cancer Drugs Market Report 2025

  • Report
  • September 2025
  • 250 Pages
  • Global
From
Pancreatic Cancer Drugs Market Report 2025 - Product Thumbnail Image

Pancreatic Cancer Drugs Market Report 2025

  • Report
  • September 2025
  • 250 Pages
  • Global
From
From
  • 6 Results (Page 1 of 1)
Loading Indicator

Gemzar (gemcitabine) is a chemotherapy drug used to treat a variety of cancers, including lung cancer. It is a nucleoside analog, meaning it works by interfering with the growth of cancer cells. Gemzar is typically used in combination with other drugs, such as cisplatin or carboplatin, to treat advanced or metastatic non-small cell lung cancer (NSCLC). It is also used to treat small cell lung cancer (SCLC) and mesothelioma. Gemzar is a widely used drug in the lung cancer market, and is often prescribed as a first-line treatment for NSCLC. It is also used in combination with other drugs to treat more advanced stages of the disease. The drug is available in both generic and brand-name formulations, and is typically administered intravenously. The Gemzar market is highly competitive, with a number of companies offering the drug. These include Eli Lilly, Bristol-Myers Squibb, Merck, Pfizer, and AstraZeneca. Show Less Read more